KYMR - Kymera Therapeutics Inc
IEX Last Trade
48.42
0.170 0.351%
Share volume: 622,969
Last Updated: Fri 30 Aug 2024 09:59:51 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$48.25
0.17
0.35%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-09 | 2022-11-03 | 2023-02-23 | 2023-05-04 | 2023-08-03 | 2023-11-02 | 2024-02-22 | 2024-05-02 | |
| Assets | |||||||||
| Total Assets | 523.421 M | 638.472 M | 603.134 M | 613.905 M | 581.945 M | 552.378 M | 575.759 M | 868.251 M | |
| Current Assets | 402.770 M | 494.022 M | 419.416 M | 411.550 M | 385.402 M | 375.694 M | 405.317 M | 537.253 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 10.461 M | 12.114 M | 9.713 M | 14.673 M | 17.828 M | 17.869 M | 11.674 M | 16.709 M | |
| Short Term Investments | 10.461 M | 12.114 M | 9.713 M | 14.673 M | 17.828 M | 17.869 M | 11.674 M | 16.709 M | |
| Total Receivables | 0.000 | 0.000 | 2.537 M | 0.000 | 0.000 | 0.000 | 18.762 M | 0.000 | |
| Current Cash | 392.309 M | 481.908 M | 407.166 M | 396.877 M | 367.574 M | 357.825 M | 374.881 M | 520.544 M | |
| Total Non-current Assets | 120.651 M | 144.450 M | 183.718 M | 202.355 M | 196.543 M | 176.684 M | 170.442 M | 330.998 M | |
| Property Plant Equipment | 12.748 M | 12.569 M | 13.334 M | 17.432 M | 27.494 M | 36.145 M | 48.134 M | 49.336 M | |
| Other Assets | 11.608 M | 12.064 M | 11.926 M | 59.759 M | 58.489 M | 57.757 M | 55.063 M | 51.447 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 523.421 M | 638.472 M | 603.134 M | 613.905 M | 581.945 M | 552.378 M | 575.759 M | 868.251 M | |
| Total liabilities | 125.470 M | 125.587 M | 112.983 M | 151.900 M | 146.517 M | 156.843 M | 180.788 M | 157.048 M | |
| Total current liabilities | 87.500 M | 91.124 M | 71.343 M | 61.933 M | 54.602 M | 63.166 M | 85.691 M | 56.136 M | |
| Accounts Payable | 2.374 M | 6.327 M | 4.335 M | 6.483 M | 3.745 M | 4.978 M | 7.075 M | 6.812 M | |
| Other liabilities | 24.335 M | 21.342 M | 28.248 M | 25.103 M | 20.651 M | 16.429 M | 16.768 M | 23.781 M | |
| Current long term debt | 3.656 M | 3.619 M | 3.943 M | 3.893 M | 3.797 M | 3.595 M | 6.345 M | 9.890 M | |
| Long term debt | 13.635 M | 13.121 M | 13.392 M | 64.864 M | 71.264 M | 77.248 M | 78.329 M | 77.131 M | |
| Other liabilities | 24.335 M | 21.342 M | 28.248 M | 25.103 M | 20.651 M | 16.429 M | 16.768 M | 23.781 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 397.951 M | 512.885 M | 490.151 M | 462.005 M | 435.428 M | 395.535 M | 394.971 M | 711.203 M | |
| Common stock | 51.772 M | 54.536 M | 57.774 M | 58.187 M | 58.327 M | 58.422 M | 58.526 M | 70.770 M | |
| Retained earnings | -305.923 M | -348.925 M | -383.790 M | -424.718 M | -463.517 M | -516.384 M | -530.752 M | -579.309 M |